# TQB2868

Source: https://onco.cc/drugs/tqb2868/  
OnCo record `tqb2868` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.

## Summary

TQB2868 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in pancreatic ductal adenocarcinoma. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: TQB2868
- Modality: Bispecific antibody
- Mechanism: A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.

## Sources

- ClinicalTrials.gov: trials of TQB2868: https://clinicaltrials.gov/search?intr=TQB2868

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms](https://onco.cc/trials/nct06767813/)

---
JSON: https://onco.cc/api/v1/entities/tqb2868.json